C-Peptide: Physiology and What Research Reports

What C-Peptide Is

C-peptide — short for "connecting peptide" — is the segment of the proinsulin molecule that links the A and B chains of insulin. Pancreatic beta cells synthesise preproinsulin, process it to proinsulin, and then enzymatically cleave out the connecting segment, leaving mature insulin plus a free 31-amino-acid peptide. A biochemistry review described C-peptide as being released into the circulation in equimolar quantities with insulin and noted that it is cleared largely by the kidney rather than by first-pass hepatic extraction, which is the reason it is used as a surrogate marker of endogenous insulin secretion (PMID 30252282).

That pharmacokinetic difference matters. Insulin is extracted substantially by the liver before reaching the peripheral circulation, so a peripheral insulin measurement underestimates beta-cell output; C-peptide is not, so it tracks secretion more faithfully (PMID 30252282). C-peptide also does not cross-react with injected insulin, meaning it can distinguish a person's own insulin production from administered insulin.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about testing, diagnosis or treatment.

Where It Is Produced and What It Does

Production is confined to the beta cells of the pancreatic islets. For decades C-peptide was treated as a metabolically inert by-product of insulin synthesis, and the biochemistry literature still frames its primary clinical role as a marker rather than a hormone with a defined receptor (PMID 30252282). A separate line of research has asked whether the peptide has biological activity of its own. A review of anti-inflammatory properties surveyed experimental work suggesting C-peptide interacts with cell signalling and influences inflammatory processes, and the authors discussed these findings in the context of diabetic complications (PMID 20039006).

How C-Peptide Is Measured and Studied

C-peptide is measured in serum, plasma or urine by immunoassay, and the measurement conditions matter. A clinical perspective on C-peptide determination reviewed how fasting, random and stimulated C-peptide values are used to help classify the type of diabetes and to inform management decisions, and described the interpretive thresholds and caveats clinicians apply (PMID 35676794).

Assay variability

Results are not interchangeable across platforms. A commentary on assay performance argued that the C-peptide assay used should be described explicitly in research and clinical reporting, because differences between methods affect comparability of results (PMID 35308000). Pre-analytical handling is also relevant: a laboratory study reported that haemolysis of the sample affected C-peptide immunoassay results, identifying sample quality as a source of measurement error (PMID 27231209).

C-Peptide in Diabetes Classification

The most established use is diagnostic. The clinical perspective review set out how C-peptide measurement helps separate insulin-deficient from insulin-resistant phenotypes and how that distinction feeds into management, including decisions about insulin dependence (PMID 35676794). Because C-peptide reflects residual beta-cell function, it is also used in research to track preservation or loss of endogenous secretion over time.

Association Studies: Inflammation, Vessels, Kidneys

A large body of observational work has examined whether C-peptide levels track with complications and risk markers.

• Myocardial injury. A study of the association between C-peptide level and subclinical myocardial injury reported a relationship between C-peptide and markers of subclinical cardiac damage (PMID 34456859).
• Peripheral atherosclerosis. Researchers examining type 2 diabetes reported a correlation between C-peptide and the severity of peripheral atherosclerosis (PMID 37663202).
• Inflammation in obesity. A study in obese women evaluated C-peptide as an inflammatory marker and reported on its relationship with inflammatory indices in that population (PMID 37601704).
• Kidney disease. A review of C-peptide and diabetic kidney disease summarised evidence and hypotheses linking the peptide to renal outcomes in diabetes (PMID 27640884).
• Breast cancer risk. An analysis of plasma C-peptide, mammographic features and breast cancer risk examined how circulating C-peptide related to mammographic characteristics and subsequent risk (PMID 39420200).

These are associations, not demonstrations of cause. Elevated C-peptide in insulin-resistant populations reflects high insulin secretion, so it can behave as a proxy for hyperinsulinaemia; the cited papers report correlations rather than establishing that C-peptide itself drives the outcomes.

Experimental Work on Direct Effects

Laboratory studies have tested whether C-peptide does something biologically rather than simply marking insulin output. One study reported that C-peptide attenuated hyperglycaemia-induced pulmonary fibrosis by inhibiting transglutaminase 2 (PMID 35266881). Another reported that proinsulin C-peptide inhibited high glucose-induced migration and invasion of ovarian cancer cells in a cell-based model (PMID 38310652). The anti-inflammatory review placed such findings within a broader argument that C-peptide may modulate inflammatory signalling relevant to diabetic complications (PMID 20039006). Findings from cultured cells and animal models do not establish clinical effects in people.

C-Peptide: What Studies Report

The verified literature summarised here is dominated by measurement, classification and association research rather than by interventional safety reporting. The clinical perspective review discussed interpretation pitfalls — including the influence of renal function on circulating levels, since clearance is renal — as part of how results should be read (PMID 35676794; PMID 30252282). On the analytical side, the study of haemolysis reported interference with C-peptide immunoassay, and the assay-performance commentary reported that inter-method differences justify naming the assay used when results are published (PMID 27231209; PMID 35308000). No dosing regimens are described on this page because the verified papers cited here did not report administration protocols in humans.

Why the Term Appears in Peptide Reading

C-peptide turns up in peptide literature for two reasons. First, it is a textbook example of a connecting peptide — a sequence whose job in the precursor molecule is structural, and which is discarded during post-translational processing; the biochemistry of that cleavage is described in the reference review (PMID 30252282). Second, it is one of the most widely measured peptides in clinical medicine, so readers encountering insulin physiology, diabetes classification or metabolic research will meet it repeatedly (PMID 35676794).

References

• Biochemistry, C Peptide (StatPearls, 2026)
• C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective (Diabetes, Obesity & Metabolism, 2022)
• Hemolysis Affects C-Peptide Immunoassay (Journal of Clinical Laboratory Analysis, 2016)
• Association Between C-Peptide Level and Subclinical Myocardial Injury (Frontiers in Endocrinology, 2021)
• Anti-inflammatory properties of C-Peptide (The Review of Diabetic Studies, 2009)
• C-peptide as an inflammatory marker in obese women (Acta Endocrinologica, 2023)
• C-peptide attenuates hyperglycemia-induced pulmonary fibrosis by inhibiting transglutaminase 2 (Journal of Molecular Endocrinology, 2022)
• The Correlation Between C-Peptide and Severity of Peripheral Atherosclerosis in Type 2 Diabetes Mellitus (Diabetes, Metabolic Syndrome and Obesity, 2023)
• Plasma C-peptide, mammographic features and risk of breast cancer (npj Breast Cancer, 2024)
• Proinsulin C-peptide inhibits high glucose-induced migration and invasion of ovarian cancer cells (Biomedicine & Pharmacotherapy, 2024)
• Which C-peptide assay do you use? Increasing need for describing C-peptide assay performance (Pediatric Endocrinology, Diabetes and Metabolism, 2022)
• C-peptide and diabetic kidney disease (Journal of Internal Medicine, 2017)